Background-Idiopathic dilated cardiomyopathy is a familial disorder in 25% to 50% of patients, but the genetic basis in the majority of cases remains unknown. Genes encoding desmosomal proteins, currently regarded as synonymous with another disorder, arrhythmogenic right ventricular cardiomyopathy, are known to cause left ventricular dysfunction, but their importance in unselected patients with unequivocal dilated cardiomyopathy is unknown. The objective of this study was to determine the prevalence of mutations in 5 desmosomal protein genes in patients with dilated cardiomyopathy. Methods and Results-We studied 100 unrelated patients with idiopathic dilated cardiomyopathy consecutively referred to a dedicated cardiomyopathy unit. Patients underwent clinical evaluation, ECG, echocardiography, exercise testing, 24-hour ambulatory ECG monitoring, and mutation screening of 5 genes implicated in arrhythmogenic right ventricular cardiomyopathy: plakoglobin, desmoplakin, plakophilin-2, desmoglein-2, and desmocollin-2. Of the 100 patients (mean age at evaluation, 46.8Ϯ13.8 years; range, 17.0 to 72.8 years; male sex, 63%), 5 were found to carry pathogenic desmosomal protein gene mutations. An additional 13 patients had sequence variants of uncertain pathogenic significance and were excluded from further comparative analysis. Patients harboring desmosomal gene mutations had a phenotype indistinguishable from the 82 noncarriers, with the exception of exercise-induced ventricular ectopy, which was more frequent in the desmosomal mutation carriers (Pϭ0.033). None of the 5 carriers of desmosomal mutations fulfilled current diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy, but 1 had fibrofatty change in the left ventricle at autopsy. Conclusions-Heart failure caused by a dilated, poorly contracting left ventricle and arrhythmogenic right ventricular cardiomyopathy have been considered distinct clinicopathologic entities. This study suggests that both clinical presentations can be caused by mutations in desmosomal protein genes. (Circ Cardiovasc Genet. 2010;3:314-322.)
I diopathic dilated cardiomyopathy (DCM) is a heart muscle disorder defined by the presence of dilatation and systolic impairment of the left or both ventricles in the absence of hypertension, coronary artery disease, or valvular abnormalities. 1, 2 The most common presentation is with signs and symptoms of heart failure, with a small minority of patients presenting for the first time with ventricular arrhythmia. Systematic screening of first-degree relatives has shown that up to 48% of patients have evidence of familial disease, but with the exception of genetic mutations associated with phenotypes such as premature conduction disease, and for a small number of patients with mutations in cytoskeletal and sarcomeric protein genes, 3 the genetic determinants of familial disease remain obscure.
Clinical Perspective on p 322
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disorder clinically defined by the presence of particular electrical, functional, and structural right ventricular abnor-malities and histologically by replacement of cardiomyocytes with fibrous or fibrofatty tissue. 4, 5 Work over the past decade has shown that ARVC is an autosomal dominant trait frequently caused by mutations in genes that encode important structural proteins found within the desmosome. 6 Although the clinical diagnosis of ARVC requires the demonstration of right ventricular disease, it is increasingly recognized that biventricular involvement is common. Indeed, in some families with desmosomal protein gene mutations, left ventricular disease may be the predominant feature. 7, 8 Based on these observations, we hypothesized that desmosomal gene mutations account for a proportion of patients whose primary clinical condition is diagnosed as DCM.
Methods

Study Population
This study was approved by the ethics committees of St George's Hospital Medical School and University College Hospitals (London, UK). All patients gave written informed consent for venesection and DNA analysis. All clinical studies were performed with investigators blinded to the results of genetic testing. The study conformed to the principles of the Declaration of Helsinki. All authors have read and agreed to the manuscript as written.
Study participants were selected from a list of 163 consecutively evaluated patients with suspected DCM referred to dedicated cardiomyopathy clinics at St George's Hospital Medical School (1989 School ( -2003 and The Heart Hospital (2003 onward). To be eligible for the study, patients had to have stored DNA samples and have fulfilled World Health Organization/International Society and Federation of Cardiology Task Force criteria for DCM (ie, a left ventricular end-diastolic diameter [LVedd] Ͼ27 mm/m 2 and an ejection fraction Ͻ40% or fractional shortening Ͻ25% in the absence of abnormal loading conditions, coronary artery disease, congenital heart lesions, and other systemic diseases). 9 Before enrollment into the study, all patients were evaluated with physical examination, chest radiography, ECG, echocardiography, 24-hour ambulatory ECG monitoring, and exercise testing. Using the formula of Henry et al, 10 the predicted LVedd was calculated for each patient from his or her height and weight and, thus, body surface area (or BSA) as follows: predicted LVeddϭ45.3ϫBSA 0.3 Ϫ0.03ϫageϫ7.2. Cardiac catheterization, angiography, endomyocardial biopsy, and cardiac MRI (CMR) were performed only if there was a clinical indication to do so. Familial disease was examined by constructing a 3-generation family tree. Death certificates and postmortem reports were sought in all cases of deaths thought to be related to DCM. On the basis of patient history and family pedigree analysis, DCM was defined as familial if 1 or more relatives (in addition to the proband) had DCM during life or at postmortem examination or had experienced unexplained sudden cardiac death (SCD) before age 35. 11 
Genetic Evaluation
Mutation screening of all exons and flanking intronic sequences of the following 5 desmosomal protein genes implicated in ARVC was carried out as described in earlier studies [12] [13] [14] : plakoglobin, desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2). After polymerase chain reaction amplification, direct sequencing of amplicons was performed on an ABI PRISM 3130 DNA analyzer using BigDye Terminator chemistry version 3.1. Primer sequences and polymerase chain reaction conditions are available on request. For every sequence variant detected in DCM probands, a cohort of 200 anonymized healthy volunteers was screened using the same methods. Individual sequence variants were considered disease causing if they predicted a premature truncation, frameshift, or abnormal splicing or had been reported previously in association with ARVC and DCM and were absent in our control population. All sequence variants were cross-referenced with an online database of mutations (www.arvcdatabase.info). 15 Sequencing variants not complying with these criteria were classified as variants of unknown significance.
Screening of Relatives
The relatives of all probands with a definite mutation were invited to undergo predictive genetic testing and clinical evaluation with a resting ECG and echocardiography after appropriate counseling. Additional tests were performed if clinically indicated.
Statistical Analysis
SPSS version 15.0 was used for all statistical analyses. Data are expressed as meanϮSD. Differences between means were compared using the Student t test and the Mann-Whitney U test for normally distributed and nonnormally distributed continuous data, respectively. Fisher exact test was used for comparison of categorical data. A 2-sided PϽ0.05 was considered significant. The authors had full access to the data and take responsibility for their integrity.
Results
Of the 163 screened patients, 100 unrelated individuals (mean age at evaluation, 46.8Ϯ13.8 years; range, 17.0 to 72.8 years; male sex, 63%) fulfilled the selection criteria. Sixty-three patients were excluded because they had left ventricular enlargement or impairment of systolic function of insufficient severity to satisfy the diagnostic criteria for DCM. Twentythree patients had familial disease, including 3 with a family history of SCD. 11 An additional 10 patients had a family history of SCD but did not fulfill the criteria for familial DCM because the deaths occurred in relatives aged Ͼ35 years. None of the patients fulfilled current diagnostic criteria for ARVC 5 or had a family history of ARVC. Five patients were found to have pathogenic mutations in PKP2 and DSP. Table 1 shows the mutations and clinical characteristics of the carriers. A further 13 patients had genetic variants of uncertain pathogenicity ( Table 2 ).
Mutations in Desmosomal Protein Genes
Three patients with DCM (Des2, Des3, and Des4) were found to carry a missense mutation in PKP2 (S140F), which has been reported previously in patients with ARVC. 16, 17 Two other patients (Des1 and Des5) had novel mutations in DSP. Des1 was heterozygous for IVS15ϩ1GϾC, which is predicted to disrupt the donor splice site of exon 15 (splice site prediction software, Neural Network 18 and SpliceView 19 ). Des5 carried a deletion that was predicted to cause a frameshift and truncation of the DSP protein at amino acid position 928 (S922fsX928). Des1 and Des4 also were heterozygous for 2 missense variants in PKP2 (H877Q) and DSP (A2712T), respectively ( Table 1) . Neither variant was present in controls.
Variants of Uncertain Pathogenicity
Thirteen additional patients had 14 sequence variants where pathogenicity was unclear ( Table 2 ). These variants included V56M in DSG2 and E896fsX900 in DSC2, which have been reported previously in patients with ARVC and left ventricular involvement as well as in controls. 12, 13, 20 Two missense changes (S169G in PKP2 and G863R in DSC2) were detected in patients with DCM and controls. The remaining 10 missense changes (including 7 novel variants) were absent in controls. Some altered highly conserved amino acid residues in desmosomal proteins (eg, G939S in DSP and V1014I in DSG2). However, in the absence of family studies to show segregation with disease and functional studies to investigate the effect of these variants on desmosomal proteins, their pathogenicity cannot be confirmed. Therefore, we excluded all patients carrying such variants from further analysis, and the remaining 82 patients with DCM were considered the noncarrier group.
Clinical Profile, Course, and Outcomes
The clinical characteristics of the 82 noncarriers and the 5 desmosomal mutation carriers are summarized in Table 3 . There were no statistically significant differences between their clinical profiles.
During follow-up, Des1 died at age 53, 14 years after his original presentation. A biventricular internal cardioverter defibrillator (ICD) was implanted 1 year earlier for conventional heart failure indications and primary prevention of SCD. His final admission was precipitated by ventricular arrhythmias and refractory cardiogenic shock. Des4 had a biventricular ICD implanted for the same indications 2 years after presentation. Ventricular arrhythmias were not detected after a follow-up period of 27 months. Des5 received an ICD for primary prevention of SCD in view of syncope, nonsustained ventricular tachycardia, and hemodynamically unstable ventricular tachycardia during an electrophysiological study. After a follow-up of 11 months, ventricular arrhythmias were not detected.
In the noncarrier group, there were 6 deaths and 2 heart transplantations for advanced heart failure. One patient died of lung cancer, but the cause of death is not known for the 5 remaining patients. In addition, 4 patients who had an ICD implanted for primary prevention had appropriate therapy for ventricular arrhythmias, and 1 patient had an ICD for secondary prevention of SCD.
ECG Characteristics
The ECG characteristics of carriers and noncarriers of pathogenic mutations were similar and are summarized in Table 3 . None of the desmosomal protein gene mutation carriers had epsilon waves, QRS prolongation Ͼ110 milliseconds, or T wave inversion in leads V1 to V3. The burden of ventricular arrhythmias was similar in both groups with the exception of ventricular ectopy during exercise, which was more frequent in desmosomal mutation carriers.
Echocardiography
Left ventricular dilatation, systolic dysfunction, and left ventricular regional wall motion abnormalities were similar in the 2 groups. Patients with right ventricular dysfunction or dilatation had a greater degree of left ventricular dilatation than patients with normal right ventricular size and function (observed LVedd and predicted LVedd by the method of Henry et al 10 expressed as percent, 142Ϯ18% and 131Ϯ19%, respectively; Pϭ0.03). The right ventricular abnormalities observed were mild, and none of the patients (carriers and noncarriers) had severe right ventricular dilation, dysfunction, or aneurysms suggestive of ARVC. The echocardiographic characteristics are summarized in Table 3 .
CMR
CMR was performed in 18 patients, and none had fatty infiltration or late gadolinium enhancement (LGE) of the right ventricle. Of the 5 desmosomal gene mutation carriers, only Des5 had a CMR that demonstrated extensive patchy epicardial LGE that became transmural inferobasally.
LGE was present in 9 noncarriers.
Histology
An autopsy performed on Des1 revealed biventricular fibrofatty infiltration (Figure 1 ). Des5 had a right ventricular endomyocardial biopsy at the time of presentation, but the histology was nonspecific. Findings from right ventricular 
Pedigree Analysis
All desmosomal protein gene mutation carriers were informed of their genetic findings, but only the families of Des1 and Des5 were available for screening. All offspring of Des1 carried the pathogenic DSP-IVS15ϩ1GϾC mutation ( Figure  2A ). II-1 and II-3 also were carriers of the PKP2-c.2630CϾA variant. II-1 was asymptomatic with a normal ECG and echocardiogram but was severely claustrophobic and unable to tolerate a CMR. II-2 had a normal echocardiogram and ECG, with 1112 premature ventricular ectopics in 24 hours. A CMR revealed posterior left ventricular wall LGE. II-3 complained of presyncope and had a nonspecific intraventricular conduction delay with a normal signal-averaged ECG and echocardiogram. In addition to LGE in the basal septum and posterior left ventricular wall, 853 premature ventricular ectopics in 24 hours were detected. II-4 was asymptomatic, with a normal ECG and echocardiogram, but a CMR showed epicardial LGE in the posterior left ventricular wall that extended to the septum ( Figure 2B ). Despite the fibrofatty change in the proband (a major diagnostic criterion for ARVC), none of the offspring had additional criteria to qualify for a diagnosis of ARVC; only II-2 had 1 extra minor criterion (Ͼ1000 ectopics in 24 hours). 5 Similarly, there was insufficient evidence to diagnose familial DCM on the basis of the premortem clinical diagnosis of the proband; only II-2 had 1 minor criterion (Ͼ1000 ectopics in 24 hours). 11 In the second family that was screened ( Figure 2C ), the mother (I-2) of the proband (Des5) was a carrier of the pathogenic DSP-c.2765_2766delCA mutation but had a normal cardiac phenotype. However, the sister (II-2), who was not a mutation carrier, reported palpitation and had mild left ventricle enlargement (an LVedd 113% of that predicted by the method of Henry et al). 10 Ambulatory ECG monitor data were not available. At the time of completion of the manuscript, II-2 had 1 minor criterion for familial DCM (LVedd Ͼ112% of that predicted) 11 and no ARVC diagnostic criteria. 5
Discussion
This study shows that a proportion of patients with an unequivocal clinical diagnosis of DCM harbor mutations in genes that encode proteins of the intercalated discs (the end-to-end connections between cardiomyocytes responsible for maintenance of mechanical and electrical integrity). These structures consist of 3 main components: the adherens junctions, the desmosome, and the gap junctions. Desmosomes are secondary mechanical intercellular junctions abundantly present in epithelial tissues and the myocardium. In 1986, genetic linkage of 9 families affected with an autosomal recessive syndromic form of ARVC led to the discovery of a homozygous 2-bp deletion that caused premature termination of translation and truncation of plakoglobin, a component of the desmosome and adherens junction. 21 Soon afterward, a mutation in a second desmosomal gene, DSP, was found to be responsible for a recessive syndromic form of ARVC (Carvajal syndrome). 22 Investigation of these and other desmo- somal protein genes in the more common autosomal dominant form of the disease resulted in the identification of mutations in DSP, 23 PKP2, 17 DSG2, 24 and DSC2 13 in up to 50% of patients. 6, 25 By definition, the right ventricle must be affected in order to make a clinical diagnosis of ARVC, but it is well recognized that left ventricular involvement is common in patients fulfilling current diagnostic criteria. Pathological examination of heart specimens at autopsy or cardiac transplantation reveals macroscopic and microscopic evidence of left ventricular involvement in up to 76% of cases. 26 More recently, a study of 200 patients with ARVC undergoing CMR reported biventricular involvement in 56% of cases and predominant left-sided disease in 5%. 7 In most cases, the posteriolateral wall of the left ventricle was the major site of involvement. It is suggested that mutations in desmosomal genes increase the susceptibility of the myocardium to the damaging effects of mechanical stress, thereby predisposing to cardiomyocyte detachment, death, and eventual replacement by fibrofatty tissue. 27 The preferential involvement of the right ventricle in ARVC has been explained by its thin wall and greater distensibility, 28 but this is unlikely to be the sole explanation for disease in either ventricle. Desmosomal proteins interact with many other proteins, including key components of the cellular cytoskeleton and intermediate filaments. 29 It is possible, therefore, that ventricular dysfunction occurs as the result of reduced cytoskeletal integrity and impaired force transduction. Some desmosomal proteins (in particular plakoglobin) are also important signaling mole- *Persistent, permanent, and paroxysmal atrial fibrillation, flutter, and supraventricular tachycardias.
†T wave inversion in at least 1 of the stated leads in the absence of bundle branch block or ventricular pacing.
‡All 5 carriers of desmosomal protein gene mutations and 67 (82%) of the noncarriers underwent an exercise test with ECG monitoring. §All 5 carriers of desmosomal protein gene mutations and 50 (61%) of noncarriers had a 24-h ambulatory ECG monitor.
Ventricular tachycardia also was detected in 2 additional noncarriers during follow-up and has no effect on significance (Pϭ0.39).
cules 30, 31 that regulate the transcription of many other genes that could conceivably play a role in the maintenance of normal myocyte function.
The findings in this study raise important questions with respect to not only the etiology of DCM, but also the terminology used to describe heart muscle disorders. Historically, heart muscle diseases are grouped into subtypes according to the morphology and function of the ventricles. ARVC is an exception in that a definitive diagnosis requires the demonstration of myocyte death and replacement by fibrofatty tissue in the right ventricle. With the identification of multiple genetic mutations in patients with all forms of cardiomyopathy, there has been a tendency to define familial heart muscle disorders according to the predominant gene or group of genes thought to be responsible. 32 However, as this study reaffirms, mutations in 1 group of genes can result in very different clinical phenotypes, and thus the term desmosomal disease can no longer be used as a synonym for ARVC.
The description of fibrofatty replacement in the left ventricle of some patients with desmosomal mutations suggests that there might be a gene-specific histology. In this study, endomyocardial biopsy was not part of the original study protocol, but postmortem examination of the heart in a single carrier of DSP-IVS15ϩ1GϾC mutation (Des1) did reveal characteristic fibrofatty changes. Endomyocardial biopsy in 1 other carrier of a desmosomal mutation (Des5) was inconclusive, but CMR showed epicardial late gadolinium hyperenhancement affecting the left ventricle in a pattern similar to the scarring observed in the postmortem specimen. Gadolinium-enhanced CMR only very recently has been used to characterize patients with DCM and was not part of the standard evaluation protocol when the blood samples were collected. Consequently, most patients in this study did not have a CMR scan performed.
We obtained a detailed family evaluation in only 2 families with desmosomal protein gene mutations. Neither pedigree was large enough to provide incontrovertible cosegregation data. In 1 family with the previously reported mutation DSP-c.2765_2766delCA, the sister of the proband (Des5) had left ventricular enlargement but was not a carrier of the mutation. In the other family (Des1), we could not complete phenotypic screening in all offspring because 1 had claustrophobia and could not undergo CMR. However, all subjects carrying the DSP-IVS15ϩ1GϾC mutation who had a CMR scan had left ventricular LGE, supporting the pathogenic nature of this genetic change. Functional studies might have helped to determine the effect of these mutations on protein function, but in vitro and animal models often do not replicate the human phenotype, and cardiac biopsy material from mutation carriers would have been required to provide definitive evidence of pathogenicity but was beyond the scope of this study.
The major clinical implication of this study is that desmosomal protein gene mutations contribute to the pathogenesis of DCM. As in ARVC, it is clear that the clinical manifestations of desmosomal protein gene mutations are variable, frequently subtle, and probably influenced by other genetic or environmental factors. For these reasons, we believe that the findings from this study should be used cautiously, particularly when considering cascade genetic screening of other family members, until further large-scale studies coupled with functional genomic studies are available.
Limitations
Our conservative approach to the interpretation of the pathogenicity of novel mutations means that we may have substantially underestimated the contribution of desmosomal protein gene mutations to the etiology of DCM. Our caution derives from data suggesting that variants in desmosomal genes are relatively common in normal populations 20, 33 and that clinical phenotypes often are absent even in carriers of known pathogenic mutations. 34 The high prevalence of compound heterozygosity in some reports also makes determination of the clinical effect of single mutations problematic. 35, 36 In this context, protein prediction software plays a role in determining pathogenicity of novel sequence variants, but as reference to the online ARVC database 37 shows, the results are software dependent and often contradictory. Nevertheless, it is likely that at least some of the additional genetic variants that were detected cause disease or act as modifiers of disease expression. For example, mutation V56M in DSG2 is 10 times more common in patients with DCM than in controls and therefore may convey increased susceptibility to disease. 20 Similarly, whereas E896fsX900 in DSC2 has been found in controls, it might still be a disease modifier because it results in truncation of the DSC2 protein and thus may disrupt binding with other desmosomal partners.
The clinical significance of the S140F variant in PKP2 is particularly controversial because it too has been reported in controls, and the affected residue is not well conserved. However, studies have suggested that the variant occurs more frequently in patients with ARVC 15 ; thus, we believe that in common with some other variants found in controls, sufficient evidence suggests that S140F is at least disease modifying if not pathogenic. The same could be said of the novel S140T variant in PKP2, which affects the same amino acid, Figure 2 . Pedigree analysis. Squares and circles indicate male and female family members, respectively. Relationships that no longer exist are indicated by a double slash across horizontal lines. Symbols with a single slash mark are deceased family members. Arrows indicate probands. The ages stated refer to age at the time of death for deceased family members and age at the time of first evaluation for living family members. ECG abnormalities are shown by symbols that are solid on the left-hand side. Left ventricular and right ventricular abnormalities on echocardiography or CMR are shown by solid symbols on the right-hand side upper and lower quadrants, respectively. Open symbols indicate unaffected family members, and symbols with a cross indicate family members who did not have a clinical evaluation. The presence (ϩ) or absence (Ϫ) of a desmosomal mutation is indicated for family members with DNA samples available for testing. A, The family tree of Des1. B, The short axis view of Des1 II-4 CMR, with LGE affecting the posterior wall and septum (white arrowheads). Her ECG and echocardiograms were normal. C, The family tree of Des5.
but in the absence of corroborative data from other studies, we coded this as a variant of uncertain significance.
It was impossible to screen all other genes associated with DCM, so we cannot exclude the possibility that some patients were compound heterozygotes for nondesmosomal gene mutations. Prospective studies combining histology, noninvasive imaging, and genotyping are now required to confirm the findings in this study.
Conclusions
Heart failure caused by a dilated, poorly contracting left ventricle and ventricular tachycardia associated with right ventricular dysfunction have been considered distinct clinicopathologic entities. This study suggests that both clinical presentations can be caused by mutations in desmosomal protein genes.
